Monthly Archives: September 2014

CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases

ORLANDO, Florida, Oct. 1, 2014 /PRNewswire/ — CORD:USE Cord Blood Bank – www.corduse.com – is pleased to announce that it has entered into an Equity and Exclusive Services Agreement with Tianhe Stem Cell Biotechnologies, Inc. (Tianhe) which has licensed a series of patented technologies for the isolation of human cord blood-derived multipotent stem cells for possible clinical applications. Tianhe is performing Phase I/II clinical trials in China and Spain using Tianhe’s Stem Cell Educator Therapy showing that the therapy is safe. In patients with moderate or severe Type 1 Diabetes (T1D), a single treatment produced lasting improvement in metabolic control. Trial results demonstrated improvement lasting three years following a single treatment. Trials also revealed improvement in 80% of patients who have Type 2 Diabetes (T2D). Initial results indicate Stem Cell Educator Therapy reverses autoimmunity and promotes regeneration of islet beta-cells with the goal of producing a treatment for T1D and T2D, as well as other autoimmune diseases.

"Tianhe is honored and thrilled to partner with CORD:USE. We have received cord blood from many banks around the nation and world, but we have found that the cord blood provided to us by CORD:USE has the highest quality of any cord blood that we have received," said Dr. Yong Zhao, President of Tianhe.

"From CORD:USE’s inception, and since we have brought together many of the world leaders in cord blood banking, research and transplantation to our team, our goal was to provide high quality, life-saving therapies for patients in need. This partnership signifies our commitment to this mission and to the cutting edge research and clinical trials necessary to provide new therapies that could benefit large populations of patients," said Edward Guindi, MD, President and CEO of CORD:USE.

The American Diabetes Association estimates that in the U.S. alone as many as 25 million people are afflicted with diabetes. The World Health Organization (WHO) reports that approximately 347 million people have diabetes worldwide and the WHO projects that it will be the 7th leading cause of death by 2030. Diabetes and its associated complications substantially affect the quality of life and create significant economic burden. Additionally, the American Autoimmune Related Diseases Association cites that 50 million Americans suffer from an autoimmune disease.

"Umbilical cord blood is a rich source of stem and progenitor cells as well as immune cell populations with tremendous potential in the treatment of many diseases including diabetes and other autoimmune diseases. CORD:USE strives to be the best in class in cord blood banking while being instrumental in the development of such new treatments," said John Wagner, MD, a pioneer in the field of umbilical cord blood transplantation.

"To date, our clinical data from trials demonstrated that correction of immune dysfunctions by Stem Cell Educator Therapy leads to the restoration of pancreatic islet β-cell function in long-standing T1D and T2D Chinese subjects. In collaboration with CORD:USE, we are going to submit the FDA application for the approval of clinical trials in the United States," said Dr. Zhao.

"We are pleased that the high-quality cord blood samples obtained from CORD:USE will allow the scientific and clinical studies to continue that may in the near future allow cord blood to be used as a source of cell therapy to effectively treat patients with diabetes and autoimmune diseases," said Dr. Hal Broxmeyer, who is recognized as a founder of the field of cord blood banking and transplantation.

About CORD:USE Cord Blood Bank, Inc.

CORD:USE Cord Blood Bank, headquartered in Orlando, Florida operates both leading high quality public and family cord blood banks. CORD:USE Cord Blood Bank has entered into agreements with hospitals across the country to provide mothers the option to donate their babies’ cord blood. CORD:USE Public Cord Blood Bank is one of the highest quality cord blood banks that has been chosen and partially funded by HRSA, of the U.S. Department of Health and Human Services, to help build the National Cord Blood Inventory. CORD:USE Family Cord Blood Bank uses the same highly advanced technologies as does their public bank. No other bank uses this combination of advanced technologies to protect cord blood. CORD:USE’s advanced technologies make it possible for them to privately store cord blood units for expectant parents from anywhere in the country and from around the world. Cord blood stem cells have been used successfully in the treatment of over 70 blood cancers and diseases. CORD:USE distributes cord blood units to transplanters, throughout the country and the world, as a critical component in their patients’ treatment. For more information, please visit our website www.corduse.com, or contact Michael Ernst at 407.667.3000.

About Tianhe Stem Cell Biotechnologies Inc.

Tianhe Stem Cell Biotechnologies Inc., an Illinois corporation, has licensed a series of patented technologies on human cord blood-derived multipotent stem cells (CB-SCs) from University of Illinois at Chicago (UIC), including the key technology Stem Cell Educator therapy. Tianhe focuses on the application of Stem Cell Educator therapy to treat diabetes and other autoimmune diseases. Tianhe is leading an international multicenter Phase II clinical trial in T1D. For more information, please visit our website www.tianhecell.com.

Logo – http://photos.prnasia.com/prnh/20141001/8521405388LOGO

Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market

— Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient.

MOUNTAIN VIEW, Calif., Sept. 30, 2014 /PRNewswire/ — Based on its recent analysis of the oncology tissue diagnostics market, Frost & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership. Adherence to strict quality practices along with a focus on innovation and improving patient safety have made Ventana a global leader in tissue-based cancer diagnostic solutions for patients worldwide.

Click here for the full multimedia experience of this release – http://ow.ly/BMQZv

As a leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments for 90 countries, and most importantly, for the four million people afflicted with cancer each year.  The company is committed to accelerating the discovery and development of new cancer diagnostic tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. 

"Ventana’s ability to discover new technology and then develop it into first-ever products aligns with the Blue Ocean Strategy for creating new markets," noted Frost & Sullivan Research Analyst, Divyaa Ravishankar "For instance, it pioneered automated staining, and was an early leader in the areas of biomarker detection chemistry and companion diagnostics. It is still the only company to provide such a wide portfolio of FDA-approved or cleared assays and algorithms."

Making the most of Roche’s worldwide infrastructure, which includes significant markets not yet served, Ventana has continued to expand its global install base of automated platforms that run advanced cancer diagnostic tests and has achieved impressive growth for the past five years. Since 2002 Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impact both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. VENTANA and the VENTANA logo are trademarks of Roche.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation

Contact:
Mireya Espinoza
P: +1-210-247-3870
F: +1-210-348-1003
E: mireya.espinoza@frost.com

Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market

— Distributors are expected to deploy a multi-sector, multi-brand strategy to broaden their business, says Frost & Sullivan

LONDON, Sept. 30, 2014 /PRNewswire/ — Established and new medical technology service providers are increasingly looking at distributors to help penetrate the growing Eastern European medical devices market. Distribution models eliminate the need for a sales team and regional/local offices, reducing the costs incurred by medical technology service providers. This is a crucial advantage as medical technology service providers are operating within a budget-constrained healthcare environment.

New analysis from Frost & Sullivan, Medical Technologies Distributor Profiles in Eastern Europe, finds that the total Eastern European medical device industry earned revenues of $5.40 billion in 2013. Market revenues will continue to expand at a compound annual growth rate of 3.1% during the 2014-2018 period. The study covers simple distributors, importers and wholesalers, and fourth-party logistics companies.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_MA5C-54_23Sept14.

"By and large, distributors handle products across multiple medical device sectors and are able to effectively address the needs of large hospitals. Their relationships with key decision-makers, doctors and nurses of many hospitals can also help distributors secure supply contracts with hospitals more easily," said Frost & Sullivan Healthcare Senior Research Analyst Parthasarathy Raghava. "This makes distributors integral to medical technology service providers’ strategies with hospitals across Eastern Europe."

New opportunities will emerge for distributors in Eastern Europe as investment grows in private healthcare. Distributors can suggest specific strategies and project rationales that will help medical manufacturers strengthen their footprint in the private sector.

However, the unwillingness of several small, family-run distributors in the industry to consolidate and expand is creating a fragmented distribution market. Some distribution companies are also limited to small markets, as they do not have enough contacts among the main decision-makers in hospitals. As such, medical device distributors across Eastern Europe must focus on building business relationships and ensure they have sufficient resources to sell products. This will be crucial as global innovation and competition in the medical devices industry maintains the need for importing new technology in Eastern European countries.

"In due course, most distributors will adopt a multi-sector, multi-brand distribution strategy to expand their customer base and boost revenues," noted Raghava. "This strategy will align well with the continuing trend of bulk purchasing by hospitals, which reduces operational complications and contains costs."

Medical Technologies Distributor Profiles in Eastern Europe is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: Automated Endoscope Reprocessor Market Trends in Western Europe, Optimisation and Efficiency Drive in Hospitals in Western Europe, Western and Eastern European Wound Care and Wound Closure Market, and Russian Arthroscopy Devices Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications — Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com

WuXi PharmaTech Announces Appointment of William R. Keller to Board

SHANGHAI, September 30, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of William Robert Keller as an independent director on the Board of Directors. He will serve on the Strategy Committee.

Mr. Keller was the general manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. from 1994 to 2003, and he served in various positions at Roche Group in South America and Asia from 1974 to 2003. He has been the vice chairman of the Shanghai Association of Enterprises with Foreign Investment, a senior consultant to the Shanghai Foreign Investment Development Board, and the deputy general manager of Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. Mr. Keller currently holds directorships at Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Coland Pharmaceutical Co., Ltd. (TWSE: 4144), and Cathay Industrial Biotech Ltd. and previously served as an independent director of China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) and Shanghai Fosun Pharmaceutical Co., Ltd. (HK: 02196). He is the founder, and since September 2003 a principal, of Keller Pharma Consultancy, a pharmaceutical consulting firm in China. He has also served as a supervisor of TaiGen Biotechnology Co., Ltd., and as chairman of HBM Biomed China Partners. Mr. Keller graduated from the School of Economics and Business Administration in Zurich. He is an honorary citizen of the city of Shanghai.

“I am delighted to join the board of WuXi PharmaTech, the leading China-based pharmaceutical R&D services company,” said Mr. Keller. “I look forward to working with my fellow directors to guide WuXi’s continuing growth.”

“We are very pleased to welcome Mr. Keller to WuXi’s board,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “His wealth of experience as an executive, director, and consultant in the pharmaceutical industry, both globally and in China, will be valuable as WuXi continues to build a comprehensive, integrated platform of services for our global life science customers.”

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. Please visit http://www.wuxiapptec.com.

For further information please contact:

Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com

Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P.

BETHESDA, Md., September 30, 2014 /PRNewswire/ — Chindex International, Inc. (“Chindex” or the “Company”) (Nasdaq: CHDX) today announced the completion of its acquisition by Healthy Harmony Holdings, L.P. (“Healthy Harmony”) for $24.00 per share in cash. Healthy Harmony is an affiliate of TPG, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun”) and Ms. Roberta Lipson, the CEO of the Company.

The previously announced merger agreement was adopted by Chindex’s stockholders at a special meeting of stockholders held on September 16, 2014. As a result of the merger, Chindex is now a privately held company, owned by Healthy Harmony, and Chindex’s common stock will be delisted from NASDAQ.

Morgan Stanley & Co. LLC served as financial advisor and Hughes Hubbard & Reed LLP served as lead legal advisor to the Transaction Committee of the Board of Directors of Chindex in connection with the merger. Goldman, Sachs & Co. served as financial advisor, Cleary Gottlieb Steen & Hamilton LLP served as lead legal advisor, and Fangda Partners served as PRC counsel to TPG. Troutman Sanders LLP served as Fosun’s legal advisor. Skadden, Arps, Slate, Meagher & Flom LLP served as lead legal advisor to Ms. Lipson.

About Chindex

Chindex is an American health care company providing health care services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. United Family Healthcare currently operates in Beijing, Shanghai, Tianjin and Guangzhou. The Company also provides medical capital equipment and products through Chindex Medical Ltd., a joint venture company with manufacturing and distribution businesses serving both domestic China and export markets. With more than thirty years of experience, the Company’s strategy is to continue its growth as a leading integrated health care provider in the Greater China region. Further Company information may be found at the Company’s website at http://www.chindex.com.

About TPG

TPG is a leading global private investment firm founded in 1992 with $66 billion of assets under management and offices in San Francisco, Fort Worth, Austin, Dallas, Houston, New York, Beijing, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, Sao Paulo, Shanghai, Singapore and Tokyo. TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, growth investments, joint ventures and restructurings. The firm’s investments span a variety of industries including financial services, travel and entertainment, technology, energy, industrials, retail, consumer, real estate, media and communications, and healthcare. Chindex is an extension of TPG’s history of investing in and adding value to leading healthcare services platforms in Asia and globally, including our investments in Parkway, Healthscope and Surgical Care Affiliates. TPG’s past and present investments in China include China Grand Auto , China International Capital Corporation, Daphne, HCP Holdings, Lenovo, Li Ning, Phoenix Satellite Television, Shenzhen Development Bank (currently Ping An Bank) and UniTrust. For more information, please visit www.tpg.com.

About Fosun Industrial

Fosun Industrial, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, was established in 2004 and registered in Hong Kong. Mr. CHEN Qiyu is the Chairman of the company. Fosun Industrial is principally engaged in foreign investment, the sales and consultation service of Chinese and Western medicine, diagnostic reagent and pharmaceutical equipment and related import and export business.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) holds 100% equity interest in Fosun Industrial. Fosun Pharma (stock code: 600196-SH ,02196-HK) is a leading healthcare company in China established in 1994 and listed on the Shanghai Stock Exchange and main board of The Stock Exchange of Hong Kong in August 1998 and October 2012, respectively. It is engaged in various businesses including pharmaceutical manufacturing, distribution and retail, healthcare services and diagnostic products and medical devices. Please visit www.fosunpharma.com for further information.

Safe Harbor Statement

Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, updates and additions to those “Risk Factors” in the Company’s interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential,” or “continue” or similar terms or the negative of these terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company has no obligation to update these forward-looking statements.

For more information, please contact:

Chindex International Inc.

ICR, LLC

William Zima
In U.S.: +1 646-308-1472
In China: +86 (10) 6583-7511
Email: william.zima@icrinc.com

TPG

Brunswick Group Limited

Siobhan Zheng
Email: tpgcoreasia@brunswickgroup.com
Tel: +852 9131-5202

Christina Pantin
Email: tpgcoreasia@brunswickgroup.com
Tel: +852 9166-3697

Shanghai Fosun Pharmaceutical (Group) Co., Ltd

Angel Yi
Email: yijy@fosunpharma.com
Tel: +86 21 23138089
Mobile: +86 13817029841

Hear from The Economist’s 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong

2014 marks the first time The Economist’s innovation initiative has come to Asia in its 13-year history

HONG KONG, Sept. 30, 2014 /PRNewswire/ — Winners of The Economist’s prestigious Innovation awards 2014 will speak at The Economist Events’ Innovation Summit scheduled to take place at the JW Marriott Hong Kong on Friday, October 10th 2014. At the summit, the award winners will share their experiences and the lessons those hold for others. The awards, which recognises outstanding people who have made a proven innovation over the past decade, will be presented at a ceremony in Hong Kong the night before the summit. It will be the first time the ceremony has come to Asia. The award winners speaking at the summit include:

Nandan Nilekani, former head of the Unique Identification Authority of India (UIDAI), has won the Social & Economic Innovation Award for his leadership of the country’s national identity scheme.

Jay Keasling, Professor of Chemical Engineering at the University of California, Berkeley and Senior Faculty Scientist, Lawrence Berkeley National Laboratory for synthetic artemisinin used to treat malaria."I was fortunate to lead a team of very talented scientists and engineers who worked long and hard to complete this high risk, high reward project," said Dr Keasling. "Because of their efforts, the lives of many people will be saved and made better. Adoption of semisynthetic artemisinin is an important step forward in eradicating malaria."

Pixar Animation Studios has won the Corporate Award for its ground-breaking computer animation tools, technology and feature films. Marc Greenberg, Vice President, Finance and Strategy, Pixar Animation Studios will speak on behalf of Pixar Animation Studios at the summit. "Pixar is honored to receive The Economist’s Corporate Innovation Award, which we accept on behalf of the studio’s incredible employees," said Marc Greenberg.  "Their creativity, commitment and drive are the source and foundation of all the company’s accomplishments."

Renaud Laplanche, Founder and CEO of Lending Club, has won the Consumer Product Award for pioneering peer-to-peer consumer lending. "Our mission is to transform the banking system to make credit more affordable and investing more rewarding, and we’re gratified that so many investors and borrowers continue to find value in that commitment," said Lending Club CEO Renaud Laplanche. "Having the impact of this disruption recognized and validated by the Economist Innovation Awards is a significant honor, and I’m excited to be recognized on behalf of all Lending Club team members."

As in The Economist newspaper, the Innovation Summit will explore innovation through the lens of what matters to senior executives in Asia, without the hype. In addition to hearing from award-winning innovators, chief executives will share corporate stories of success and failure — with insight on how to learn from both. Entrepreneurs will share how to think like the competition in order to not be beaten by it. Participants will survey where disruption is heading in Asia and suggest how to avoid the shocks. The right role for government in spurring innovation will be examined and the latest breakthrough technologies will be revealed. Finally, The Economist will challenge the prevailing assumption that innovation is good and plentiful by debating the provocative notion that "We are not as innovative as we think".

Other featured speakers include:

  • Fanny Law, Member, HKSAR Executive Council, Chairperson, Hong Kong Science & Technology Parks Corporation
  • Tom Standage, Online and Digital Editor, The Economist
  • Vijay V Vaitheeswaran, Author of Need, Speed, and Greed, China Business Editor and Shanghai Bureau Chief, The Economist Guo Ping, Deputy Chairman of the Board, Rotating Chief Executive Officer, Huawei Nisaba Godrej, Executive Director, Godrej Consumer Products
  • Kevin Goldmintz, Chief Executive Officer, Octopus
  • K. R. Sanjiv, Chief Technology Officer, Wipro Raj Thampuran, Managing Director, Agency for Science, Technology and Research
  • Scott Anthony, Managing Partner, Innosight
  • William Saito, Founder and Chief Executive Officer, InTecur K.K., Special Advisor, Cabinet Office for Government of Japan Toshiyuki Inoko, Founder, teamLab Andrew Chung, Managing Partner, Khosla Ventures Sirgoo Lee, Co-Chief Executive Officer, Daum Kakao
  • David Jensen, Global Innovation and Digital Strategy Leader, EY
  • Viren Shetty, Senior Vice President, Strategy and Planning, Narayana Hrudayalaya Tyler Cowen, Author, Professor of Economics, George Mason University
  • Parag Khanna, Managing Partner, Hybrid Reality, Senior Fellow, New America Foundation

First time in Asia

Innovation is an increasingly global activity. No city, country or region has a monopoly on "new ideas that create value", as The Economist likes to define it. The awards, the only awards presented by the newspaper, and the summit reflects that fact in its choice of location as well as its content.

"Unlike other awards ceremonies and conferences, our focus is not simply on promising innovations that might turn out to be important," says Tom Standage, Online and Digital Editor of The Economist. "Rather, our focus is on proven innovations that have demonstrated their value — and the lessons that can be learned from them. In other words, we look backwards in order to look forwards."

The Economist Intelligence Unit will be releasing a white paper Under the radar: Innovation in Asia evolves at the summit.

For further information on the awards and summit please visit the website: economistinsights.com/innovation2014.

Huawei and EY are sponsors for The Economist’s Innovation Awards and Summit 2014. InvestHK is the host sponsor.

About The Economist‘s Innovation Awards

In this annual awards programme, The Economist showcases creative people who dream up new ideas and turn them into reality. The newspaper invites its readers to nominate outstanding innovators in seven categories: Bioscience, Computing and Telecommunications, Consumer Products, Energy and the Environment, Process and Service Innovation, Social and Economic Innovation, and a special "no boundaries" category for innovations that span industries and sectors. In addition, the judges select the winner of the corporate award for innovation.

This year’s award judges included Tom Standage, Online and Digital Editor, The Economist; Vijay Vaitheeswaran, China Business and Finance Editor, The Economist; Hernando de Soto, Chairman, Institute for Liberty and Democracy; Hongyang Wang, Director, National Center for Liver Cancer, China Department of Health Science; and Lesa B. Roe, Director, Langley Research Center, NASA. To see the full judging panel, please visit the awards’ website: http://economistinsights.com/innovation2014.

Over the past 13 years, The Economist‘s Innovation Awards programme has recognised the work of the world’s leading entrepreneurs, thinkers, creators, scientists and innovators, including Steve Jobs, Mark Zuckerberg, Hernando de Soto and Elon Musk.

About Nandan Nilekani and the identity system

UIDAI was set up in 2009 with the aim of issuing everyone in India, especially the poorest residents in rural areas, a unique identification number. This would enable them to prove their identity in order to do things like open a bank account or get credit. Mr Nilekani led the team to create a biometric database of personal identities relying on fingerprints and iris scans.

The identity system can both reduce fraud and allow for the provision of vastly improved public services. When people have valid identification and bank accounts, government payments can go directly to them rather than into the pockets of intermediaries who have invented imaginary ghost workers or welfare recipients. Direct payments also allow people to be more mobile and leave their home village to seek work without forfeiting any benefits.

About Jay Keasling’s discovery

Artemisinin is the main ingredient used in drugs for treating malaria. But the natural supply of artemisinin is limited and inconsistent. Dr Keasling discovered how to synthesise small amounts of artemisinic acid, and formed a company named Amyris to develop the biological process. In December 2004 the Bill & Melinda Gates Foundation gave US$42.6 million to fund its research. Amyris was able to boost artemisinic acid production by a factor of 15. This led to large-scale production of semi-synthetic artemisinin.

Dr Keasling’s work has led to a major advance in the treatment of malaria, which affects an estimated 250 million people a year. It will increase and stabilise the supply of artemisinin, and lower the cost of this key malaria treatment.

About Pixar Animation Studios

Pixar has produced many significant technological breakthroughs, including computer graphics software that enables production of animated images of unparalleled quality, richness and vibrancy. Every Academy Award® winner for Visual Effects in the past 15 years has used Pixar’s suite of RenderMan products.

Pixar also changed the way animated films were made by launching its own short and then full-length animated feature films created entirely with computer technology. Its first feature film, "Toy Story," was the highest-grossing movie of 1995. Pixar has earned 30 Academy Awards®, including seven for Best Animated feature, six Golden Globe Awards and 11 Grammy Awards.

About Renaud Laplanche and the Lending Club

In 2006, Renaud Laplanche noticed that if he carried a balance on his bank credit card he would pay 16.49% interest, yet the same bank would pay him interest of only 0.48% on his savings account. Intrigued by the huge spread, he built an online peer-to-peer marketplace called Lending Club that connects borrowers and investors, efficiently connecting the supply and demand of capital.     

Most borrowers use Lending Club to access affordable credit.  All of the loans offered through Lending Club’s marketplace feature fixed rates, fixed monthly payments, no hidden fees and no prepayment penalties.  Lending Club delivers value to investors by providing them with the opportunity to earn attractive risk-adjusted returns.  Between its launch and June 30th 2014, Lending Club facilitated $5 billion in loans.

Media Contact:

Stefanie Wong
Phone Number: +852-2837-4773
Email: Stefanie.wong@edelman.com

U.N. Biodiversity Convention Opens in S. Korea

SEOUL, South Korea, Sept. 30, 2014 /PRNewswire/ — Some 20,000 government officials, environmentalists and businesspeople from around the world gathered in the eastern city of Pyeongchang on Monday for a U.N. environmental convention on biodiversity, the environment ministry said.

The 12th meeting of the Conference of the Parties to the Convention on Biological Diversity, dubbed COP 12, kicked off with a ceremony for a 19-day run, with about 20,000 representatives from 194 countries attending, the ministry said.

During the conference themed "Biodiversity for sustainable development," the participants will address agenda items that include a midterm evaluation of a 2011-2020 strategic plan for biodiversity and the application of the biodiversity goals to the post-2015 U.N. sustainable development goals.

The Convention on Biological Diversity (CBD), informally known as the Biodiversity Convention, was adopted at the U.N. Conference on Environment and Development (UNECD) held in Brazil in 1992 to address environmental problems facing the planet.

The multilateral treaty handling all aspects of biological diversity, including genetic resources, species and ecosystems, is one of the three U.N. conventions aimed at protecting the environment along with the Framework Convention on Climate Change and the Convention to Combat Desertification.

Also to be held during the Pyeongchang conference is the 7th meeting of the Conference of the Parties to the Cartagena Protocol on Biosafety (Sept. 29-Oct. 3) and the first meeting of the Conference of the Parties to the Nagoya Protocol on Access and Benefit-sharing (Oct. 13-17).

The COP 12 will adopt a "Pyeongchang Road Map" that sets out ways to achieve U.N. sustainable development goals and a "Gangwon Declaration" containing the results of the conference.

The Gangwon Declaration is expected to include the South Korean government’s interest in the preservation of biodiversity in the Demilitarized Zone (DMZ) located at the inter-Korean border.

"South Korea will make it an eco-friendly conference and a chance to enhance the value of preserving biological diversity in the world," said Kim Sang-hoon, director general of the Korean Secretariat of the U.N. Biodiversity Conference 2014.

"We expect this will be a good opportunity for Gangwon Province to increase the world’s awareness of Pyeongchang, the host city of the 2018 Winter Olympics in the province, and its capacity to host a large-scale international event ahead of the Olympics."

Media Contact

Seo, yun-sik
supersik@korea.kr
+82-2-779-1386

Citation Growth: antibodies-online.com in Top 10 According to Pivotal Scientific Antibody Market Report

AACHEN, Germany, ATLANTA and SHANGHAI, September 30, 2014  /PRNewswire/ —

According to the latest Pivotal Scientific Antibody Market Report, antibodies-online.com, the largest online distributor for proteomics research products worldwide, is ranked 6th regarding citation growth. Pivotal Scientific, a biotechnology consultancy that works specifically with research reagent manufacturers, investigated the fastest growing companies in terms of citations published in 2014. Companies offering products associated with at least 100 references in peer-reviewed scientific publications were considered in this study.

"We are very proud, that the Pivotal Scientific Antibody Report ranked us 6th," says Dr. Tim Hiddemann, co-founder of antibodies-online.com. "The ranking shows the relevance of products on antibodies-online.com for scientists."

antibodies-online supports researchers in making informed decisions based on solid product data by providing exhaustive background information on how the product has been applied in previous experiments. In an additional effort to increase product quality and data transparency the online-distributor partnered with Science Exchange to launch the Independent Validation Initiative. This program facilitates independent testing and validation of commercially available antibodies and ELISA kits through cooperation with leading laboratories in the United States.

Offering more than 1 million antibodies, ELISA kits and related research reagents from more than 160 suppliers like BD Biosciences, Abnova and BioVision antibodies-online.com is the largest independent distributor for proteomics research worldwide, currently serving over 2,000 companies and research institutions in 53 different countries. Current customers include pharmaceutical and biotech research firms like Applied Proteomics and Roche Diagnostics and leading Universities and life-science research institutions like Vanderbilt University, Duke University, Deutsche Krebsforschungszentrum (DKFZ) and Cancer Research UK. antibodies-online.com currently operates out of three global offices in Atlanta (USA), Aachen (Germany) and Shanghai (China).

Media Contact

Patrik von Glasow
PR Manager, antibodies-online Inc.
Tel: +1-404-474-4654
Fax: +1-888-205-9894
Email: patrik.vonglasow@antibodies-online.com

Chinese Clinics and Cancer Patients to Benefit from Elekta’s Versa HD Radiation Therapy System

— Advanced treatment system now available in Elekta’s second largest market

BEIJING, Sept. 30, 2014 /PRNewswire/ — Following US and European approvals of Elekta’s Versa HD™ linear accelerator, the China Food and Drug Administration (CFDA) has cleared the radiation therapy system for sale and marketing in the country.

According to the International Agency for Research on Cancer, well over three million people are diagnosed with cancer every year in China1, the most common types including lung, gastric, colorectal, liver and esophageal cancers2. Versa HD is designed to improve patient care and treat a wide range of tumors throughout the body.

Versa HD is equipped with the Agility™ multileaf collimator for high-speed, high-precision beam shaping to support extremely accurate tumor targeting and improved healthy tissue preservation. Together with High Dose Rate mode, Versa HD is able to improve clinical workflow by providing rapid delivery of more sophisticated therapies within standard radiotherapy treatment times.

Elekta’s Anming Gong, Managing Director for China, says: "As cancer rates continue to rise in China, the need for advanced and effective treatment becomes even greater. Versa HD will help support the government’s health care reform, which includes upgrading community and rural health care facilities by 2020."

Versa HD has been overwhelmingly popular since its launch in 2013, with shipments made to 30 countries. Elekta has been present in China since 1982 and eight of 10 top cancer centers have Elekta linear accelerators. The introduction of Versa HD will strengthen Elekta’s leading position in the Chinese market.

1

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.

2

Report of incidence and mortality in China cancer registries, 2009 (doi: 10.3978/j.issn.1000-9604.2012.12.04)

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on September 29, 2014.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.